Please use this identifier to cite or link to this item: https://oxfordhealth-nhs.archive.knowledgearc.net/handle/123456789/129
Full metadata record
DC FieldValueLanguage
dc.contributor.advisor
dc.contributor.authorCipriani, Andrea
dc.date.accessioned2018-10-31T11:48:58Z
dc.date.available2018-10-31T11:48:58Z
dc.date.issued2018
dc.identifier.citationCipriani, Andrea; Adamo, Nicoletta; Del Giovani, Cinzia; Goghill, David; Banaschewski, Tobias; Hollis, Chris; Zuddas, Alessandro; Simonoff, Emily; Cortese, Samuele. Unbalanced risk-benefit analysis of ADHD drugs – Authors' reply. Lancet Psychiatry Correspondence 2018 5(11)P871-873en
dc.identifier.urihttps://oxfordhealth-nhs.archive.knowledgearc.net/handle/123456789/129
dc.descriptionPublished online at: DOI: 10.1016/S2215-0366(18)30396-1 This is an Open Access article under the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/). Copyright © 2018 Elsevier Ltd. All rights reserved.en
dc.description.abstractStandardised mean differences can be difficult to translate into clinical practice. As reported in the Cochrane handbook, the mean difference (or more correctly, difference in means) measures the absolute difference between the mean value in two groups and then estimates the average amount that the experimental intervention changes in the outcome compared with that of the control intervention.en
dc.description.sponsorshipSupported by the NIHR
dc.language.isoenen
dc.subjectRisk Assessmenten
dc.subjectAttention Deficit Hyperactivity Disorder (ADHD)en
dc.titleUnbalanced risk-benefit analysis of ADHD drugs – Authors' replyen
dc.typeArticleen
Appears in Collections:Drug Therapy

Files in This Item:
File Description SizeFormat 
ADHD Author Response.pdfADHD drugs - Author's Response54.83 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.